Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$1B |
| 2 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$539M |
| 3 |
Alibaba
BABA
|
+$476M |
| 4 |
AGN
Allergan plc
AGN
|
+$464M |
| 5 |
Perrigo
PRGO
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$777M |
| 2 |
Merck
MRK
|
+$766M |
| 3 |
AGN
Allergan Inc
AGN
|
+$573M |
| 4 |
SLB Ltd
SLB
|
+$551M |
| 5 |
TJX Companies
TJX
|
+$521M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.12% |
| 2 | Consumer Discretionary | 14.46% |
| 3 | Technology | 12.11% |
| 4 | Communication Services | 11.75% |
| 5 | Financials | 9.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZOES
476
DELISTED
Zoe's Kitchen, Inc.
ZOES
| $12M | 0.01% |
402,554
+100,843
| +33% | +$3.27M |
|
477
Insmed
INSM
$21.4B
| $11.8M | 0.01% |
762,603
-37,835
| -5% | -$537K |
|
|
LMOS
478
DELISTED
Lumos Networks Corp
LMOS
| $11.3M | 0.01% |
671,602
-421,882
| -39% | -$6.9M |
|
|
WBC
479
DELISTED
WABCO HOLDINGS INC.
WBC
| $10.8M | 0.01% |
103,535
-211,558
| -67% | -$20.9M |
|
|
EGRX
480
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $10.7M | 0.01% |
688,843
-551
| -0.1% | -$7.04K |
|
|
ANAC
481
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $10.7M | 0.01% |
+330,836
| New | +$9.93M |
|
|
DSCI
482
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $10.6M | 0.01% |
1,136,666
-12,648
| -1% | -$110K |
|
|
DBVT
483
DBV Technologies
DBVT
$799M
| $10.1M | 0.01% |
+37,257
| New | +$9.58M |
|
|
CBAY
484
DELISTED
Cymabay Therapeutics
CBAY
| $9.77M | 0.01% |
993,500
-6,500
| -0.7% | -$52.3K |
|
485
Qualys
QLYS
$5.1B
| $9.52M | 0.01% |
252,092
-106,378
| -30% | -$3.55M |
|
|
DERM
486
DELISTED
Dermira, Inc.
DERM
| $9.49M | 0.01% |
+523,978
| New | +$8.76M |
|
487
Madrigal Pharmaceuticals
MDGL
$10.8B
| $9.35M | 0.01% |
100,852
-4,116
| -4% | -$426K |
|
488
Larimar Therapeutics
LRMR
$397M
| $9.01M | 0.01% |
24,338
-9,342
| -28% | -$2.41M |
|
489
Tandem Diabetes Care
TNDM
$1.34B
| $8.89M | 0.01% |
69,997
-57,207
| -45% | -$7.93M |
|
|
SPNC
490
DELISTED
Spectranetics Corp
SPNC
| $8.87M | 0.01% |
+256,456
| New | +$7.99M |
|
491
Q2 Holdings
QTWO
$3.8B
| $8.71M | 0.01% |
+462,285
| New | +$7.87M |
|
492
MPLX
MPLX
$59.3B
| $8.38M | 0.01% |
113,977
-66,365
| -37% | -$4.23M |
|
|
PSXP
493
DELISTED
PHILLIPS 66 PARTNERS LP
PSXP
| $8.18M | 0.01% |
118,734
-54,258
| -31% | -$3.53M |
|
494
NETSCOUT
NTCT
$2.96B
| $7.95M | 0.01% |
217,551
-288,665
| -57% | -$10.9M |
|
495
Atara Biotherapeutics
ATRA
$75.5M
| $7.86M | 0.01% |
+11,748
| New | +$7.17M |
|
496
Assembly Biosciences
ASMB
$498M
| $7.03M | 0.01% |
74,493
+41,160
| +123% | +$4.06M |
|
|
FCSC
497
DELISTED
Fibrocell Science Inc.
FCSC
| $6.86M | 0.01% |
178,646
-5,674
| -3% | -$229K |
|
498
Enbridge
ENB
$119B
| $6.83M | 0.01% |
132,826
-1,120,173
| -89% | -$52.8M |
|
|
RGLS
499
DELISTED
Regulus Therapeutics
RGLS
| $6.45M | 0.01% |
3,351
+658
| +24% | +$1.17M |
|
|
ETP
500
DELISTED
Energy Transfer Partners L.p.
ETP
| $6.31M | 0.01% |
97,138
+24,499
| +34% | +$1.57M |
|
Similar funds
Jennison Associates's Q4 2014 Portfolio in Review
As of Q4 2014, Jennison Associates held 806 positions worth $107B, down 0.8% from $108B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates withdrew a net $3.79B in Q4 2014, closing 91 positions and reducing 351 holdings. Its most notable exit was Oneok, an estimated $184M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 19% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, Jennison Associates opened a new position in Shire pic worth $1B.
- Jennison Associates's largest Q4 2014 buy was Shire pic: 4,721,078 shares worth $1B.
- Jennison Associates added most to Alibaba in Q4 2014, an estimated $476M increase.
- Jennison Associates's biggest Q4 2014 reduction was Alphabet (Google) Class C, cutting an estimated $777M.
- Jennison Associates fully exited Oneok in Q4 2014, selling an estimated $184M.
- Jennison Associates's ten largest holdings make up 20% of its $107B portfolio in Q4 2014.
- Jennison Associates opened 89 new positions and closed 91 in Q4 2014.
- Jennison Associates's portfolio value fell 0.8% quarter-over-quarter to $107B.
Based on Jennison Associates's 13F filing for Q4 2014, filed 6 Feb 2015.